<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03379012</url>
  </required_header>
  <id_info>
    <org_study_id>KCRB08022016</org_study_id>
    <nct_id>NCT03379012</nct_id>
  </id_info>
  <brief_title>Testosterone in Metastatic Renal Cell Carcinoma Patients</brief_title>
  <acronym>FARETES</acronym>
  <official_title>Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kidney Cancer Research Bureau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kidney Cancer Research Bureau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose

      To determine efficacy and safety of Testosterone in male patients with metastatic renal cell
      carcinoma and fatigue receiving targeted therapy or checkpoint inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue is a frequent symptom of metastatic renal cell carcinoma (RCC), and most common
      adverse event of targeted and immunotherapy.

      In Phase 3 pivotal studies, 56% (9%, grade 3-4), 54% (11%, grade 3), 37% (10%, grade 3-4) and
      20% (2%, grade 3) of patients had fatigue during the therapy of cabozantinib, sunitinib,
      axitinib or pazopanib, respectively. 59% (14%, grade 3) and 31% (5%, grade 3) of patients
      treated with lenvatinib/everolimus and everolimus had fatigue in registrational trials.
      Finally, 33% (2%, grade 3-4) of patients that received nivolumab had fatigue in CheckMate 025
      study.

      Testosterone may help to relieve fatigue associated with the use of tyrosine kinase, mTOR or
      checkpoint inhibitors. Additionally, testosterone could impact on poor prognostic factors of
      RCC (anemia, ECOG performance status, serum calcium). This will be first clinical trial which
      evaluates safety and efficacy of Testosterone in RCC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2016</start_date>
  <completion_date type="Anticipated">July 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in mean change of Fatigue from baseline score with testosterone vs. without testosterone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>3 months</time_frame>
    <description>Safety and tolerability of testosterone (CTCAE v.4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Health-related quality of life (NCCN-FACT FKSI-19 (Version 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rate of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Overall rate of adverse events related with TKI treatment (CTCAE v.4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone serum concentrations</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximum and minimum total testosterone serum concentrations following dose administration at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell count and Hemoglobin concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in Red blood cell count and Hemoglobin concentration following dose administration at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in serum calcium concentration following dose administration at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG PS</measure>
    <time_frame>3 months</time_frame>
    <description>ECOG Performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Testosterone and Targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Targeted therapy (sunitinib or pazopanib) only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate and sunitinib or pazopanib</intervention_name>
    <description>Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)</description>
    <arm_group_label>Testosterone and Targeted therapy</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven clear cell renal cell carcinoma;

          2. CT-confirmed metastatic measurable disease;

          3. First-line sunitinib or pazopanib treatment with fatigue;

          4. Low level of testosterone;

        4. Male, 18 years and older; 5. Normal PSA level

        Exclusion Criteria:

          1. Prostate and other cancers history

          2. Hypothyroidism

          3. History of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or
             other severe cardiovascular disease (i.e., New York Heart Association class III or IV)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilya Tsimafeyeu</last_name>
    <email>kidneycancer@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.I. Kryzhanovsky Krasnoyarsk Cancer Center</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruslan Zukov</last_name>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney Cancer Research Bureau</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilya Tsimafeyeu</last_name>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RUDN University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Tishova</last_name>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Center</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Borisov</last_name>
      <email>kidneycancer@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.</citation>
    <PMID>27279544</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24.</citation>
    <PMID>17215529</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254.</citation>
    <PMID>23598172</PMID>
  </reference>
  <reference>
    <citation>Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013 Apr;49(6):1287-96. doi: 10.1016/j.ejca.2012.12.010. Epub 2013 Jan 12.</citation>
    <PMID>23321547</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.</citation>
    <PMID>26482279</PMID>
  </reference>
  <reference>
    <citation>Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219.</citation>
    <PMID>20549832</PMID>
  </reference>
  <reference>
    <citation>Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol. 2017 Jul 1;47(7):639-646. doi: 10.1093/jjco/hyx049.</citation>
    <PMID>28419248</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

